Biocon Biologics, a subsidiary of India-based Biocon Ltd, said on Thursday that U.S. FDA has approved Jobevne, a biosimilar ...

Drugmakers' stocks in Europe and India slipped on Wednesday after U.S. President Donald Trump reiterated plans for a "major" ...

Biocon Biologics has received the Food and Drug Administration’s green light for Jobevne (bevacizumab-nwgd), a biosimilar ...

Biocon Biologics, a subsidiary of Biocon Ltd, announced on Thursday that it has received approval from the United States Food ...

Biocon Biologics, the biosimilar arm of Biocon has expanded its oncology portfolio with the USFDA approval of Jobevne, a ...

FDA approves Biocon Biologics' Jobevne, a biosimilar Bevacizumab for cancer treatment, expanding access to affordable ...

Biocon Biologics receives USFDA approval for Jobevne (bevacizumab-nwgd), a biosimilar Bevacizumab for treating various ...

Biocon Biologics on Thursday said it has received an approval from the US health regulator to market a cancer treatment ...

The US sales of bevacizumab were around $2 billion in 2023. Amgen, Amneal, Celltrion and Pfizer are its competitors in the US ...

Glenmark and Biocon are recalling products in the US due to manufacturing issues. USFDA initiated Class II recalls for ...

Biocon Biologics (BBL), a subsidiary of Biocon, today announced that the U.S. Food and Drug Administration (U.S. FDA) has approved Jobevne (bevacizumab-nwgd), a biosimilar Bevacizumab for intravenous ...

Biocon Biologics, a subsidiary of Biocon, has scored a major win with the U.S. FDA approving JOBEVNE (bevacizumab-nwgd), a biosimilar to Roche's blockbuster cancer drug Avastin.